Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Discovery
Boundless Bio raises $105 million to target DNA circles
by Ryan Cross
April 30, 2021
| A version of this story appeared in
Volume 99, Issue 16
San Diego–based Boundless Bio has raised $105 million in series B financing to continue developing small-molecule therapies that target unusual DNA circles found in cancer called extrachromosomal DNA (ecDNA). The circles often contain cancer-promoting oncogenes that allow tumors to rapidly develop resistance to cancer therapies. Boundless has identified three targets related to ecDNA that it is developing drugs against and is using synthetic lethality screens to identify more targets. The new financing will also help Boundless develop a companion diagnostic to identify tumors with ecDNA.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter